MARKET

INFI

INFI

Infinity Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.190
+0.020
+1.71%
Opening 11:52 08/12 EDT
OPEN
1.220
PREV CLOSE
1.170
HIGH
1.230
LOW
1.170
VOLUME
747.72K
TURNOVER
--
52 WEEK HIGH
1.680
52 WEEK LOW
0.6000
MARKET CAP
68.35M
P/E (TTM)
-1.5772
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INFI stock price target is 2.500 with a high estimate of 3.500 and a low estimate of 1.000.

EPS

INFI News

More
3 “Strong Buy” Penny Stocks With Triple-Digit Upside Potential
Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask. There’s no middle ground when it comes to these tickers trading for less than $5 per share; those on the Street are either fans or harsh critics.Both sides make sense. The naysaye
TipRanks · 1d ago
Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/31 05:13
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 22:30
Infinity Pharmaceuticals Q2 EPS $(0.16) Beats $(0.19) Estimate, Sales $360.00K Beat $160.00K Estimate
Infinity Pharmaceuticals (NASDAQ:INFI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 11.11 percent increase over losses of $(0.18) per
Benzinga · 07/30 20:25
Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral imm
Business Wire · 07/30 20:05
Infinity Pharmaceuticals EPS beats by $0.04, beats on revenue
Seeking Alpha · 07/30 04:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Infinity Announces the Date of Its Second Quarter Financial Results Conference Call and Webcast
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on July 30, 2020 at 4:30 p.m. ET to review its second quarter 2020 financial results and provide an update on the company.
Business Wire · 07/23 11:35

Industry

Biotechnology & Medical Research
+0.08%
Pharmaceuticals & Medical Research
+1.33%

Hot Stocks

Symbol
Price
%Change

About INFI

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
More

Webull offers kinds of Infinity Pharmaceuticals Inc. stock information, including NASDAQ:INFI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INFI stock methods without spending real money on the virtual paper trading platform.